Azenta Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Azenta de 110% y 4.2% por año respectivamente. Se prevé que el BPA crezca en un 106.3% al año. Se espera que la rentabilidad financiera sea de 0.6% en 3 años.

Información clave

110.0%

Tasa de crecimiento de los beneficios

106.34%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	18.7%
Tasa de crecimiento de los ingresos	4.2%
Rentabilidad financiera futura	0.62%
Cobertura de analistas	Low
Última actualización	24 Aug 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Actualización de narrativa • Sep 03

AZTA: Leadership Transition And Index Inclusion Will Shape A Measured Sentiment Recovery

Analysts have raised their price target on Azenta stock to $35 from $28, citing updated assumptions around fair value and valuation multiples that support the higher target. What’s in the News for Azenta Azenta appointed Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta as an executive officer and director.

Actualización de narrativa • Aug 18

AZTA: Higher Guidance And Buybacks Will Offset Future P/E Compression Risks

Analysts have raised the fair value estimate for Azenta from $20.00 to $33.00. They highlighted a recent increase in the Street price target to $35.00 as support for this higher assessment.

Seeking Alpha • Aug 14

Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue

Summary AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out. There is reason to suspect the rally could undergo a reversal, which is why I am neutral on AZTA with a hold rating. Read the full article on Seeking Alpha

Actualización de narrativa • Aug 04

AZTA: Index Additions And Refined Assumptions Will Support Gradual Sentiment Recovery

Analysts have raised their price target for Azenta from $26.20 to $27.80, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that they view as better reflecting the stock's risk and return profile. What’s in the News for Azenta Robotics and software automation business Brooks Automation, which previously housed the life sciences operations that were later renamed Azenta, is reported by Bloomberg to be considering an IPO, according to periodical coverage.

Actualización de narrativa • Jul 21

AZTA: Portfolio Refocus And Index Additions Will Support Future Upside Potential

Analysts have reduced their price target for Azenta to $33 from $45. This change reflects updated assumptions for slightly higher discount rates, more moderate revenue growth, softer profit margins, and a lower projected future P/E multiple.

Actualización de narrativa • Jul 07

AZTA: Future P/E Compression And Impairment Charges Will Pressure Returns

Analysts have reduced their price target for Azenta from $30 to $20, citing updated assumptions that include a slightly higher discount rate, more modest revenue growth expectations, a marginally revised profit margin outlook, and a lower future P/E estimate. What’s in the News for Azenta Azenta, Inc.

Actualización de narrativa • Jun 23

AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery

The latest Narrative Update on Azenta reflects a lower analyst price target, with recent Street research trimming estimates by $5 to $10 as analysts factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Azenta points to a more cautious stance on valuation, with reduced price targets reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.

Actualización de narrativa • Jun 09

AZTA: 2026 Execution Reset And Impairment Resolution Will Support Sentiment Recovery

Analysts have reduced their average price target on Azenta by $15, reflecting updated views on the stock's risk profile and earnings power. Analyst Commentary Recent Street research on Azenta has centered on lower price targets and a reassessment of the stock's risk and earnings outlook.

Actualización de narrativa • May 25

AZTA: 2026 Guidance And Calibrated Expectations Will Support Sentiment Recovery

Analysts have reduced their price targets on Azenta by $10 and $5 in recent research. The updated fair value estimate of $26.20 reflects more cautious assumptions on revenue growth and profit margins, even as the projected future P/E edges higher.

Actualización de narrativa • May 01

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.

Actualización de narrativa • Apr 15

AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery

Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.

Actualización de narrativa • Apr 01

AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery

Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.

Actualización de narrativa • Mar 18

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.

Actualización de narrativa • Mar 03

AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery

Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.

Nueva narrativa • Feb 25

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?

Actualización de narrativa • Feb 17

AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside

Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.

Nueva narrativa • Feb 08

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?

Actualización de narrativa • Feb 03

AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential

Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.

Actualización de narrativa • Jan 20

AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward

Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.

Actualización de narrativa • Jan 05

AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential

Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.

Actualización de narrativa • Dec 14

AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion

Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.

Actualización de narrativa • Nov 29

AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026

Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.

Artículo de análisis • Nov 28

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...

Actualización de narrativa • Nov 14

AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity

Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.

Actualización de narrativa • Oct 30

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.

Artículo de análisis • Sep 12

Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...

Artículo de análisis • Aug 07

Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...

Artículo de análisis • Jul 24

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...

Artículo de análisis • Nov 14

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:AZTA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2028	673	13	43	83	3
9/30/2027	641	16	41	77	5
9/30/2026	615	-164	42	66	5
6/30/2026	614	-112	10	38	N/A
3/31/2026	596	-111	30	62	N/A
12/31/2025	595	26	31	63	N/A
9/30/2025	594	24	38	72	N/A
6/30/2025	586	-28	52	88	N/A
3/31/2025	586	-28	39	72	N/A
12/31/2024	579	-24	32	66	N/A
9/30/2024	573	-24	12	50	N/A
6/30/2024	595	-21	24	62	N/A
3/31/2024	616	-23	31	69	N/A
12/31/2023	628	-9	10	48	N/A
9/30/2023	551	-8	-34	6	N/A
6/30/2023	630	-21	-56	-13	N/A
3/31/2023	597	-26	-500	-449	N/A
12/31/2022	594	-25	-581	-509	N/A
9/30/2022	555	-11	-543	-466	N/A
6/30/2022	555	-28	-530	-449	N/A
3/31/2022	551	-23	-59	16	N/A
12/31/2021	535	-29	66	122	N/A
9/30/2021	514	-29	97	150	N/A
6/30/2021	114	-69	130	175	N/A
3/31/2021	205	-53	112	156	N/A
12/31/2020	296	-37	10	56	N/A
9/30/2020	389	-26	-2	38	N/A
6/30/2020	850	41	-19	19	N/A
3/31/2020	834	28	N/A	29	N/A
12/31/2019	812	16	N/A	110	N/A
9/30/2019	334	-61	N/A	91	N/A
6/30/2019	741	3	N/A	89	N/A
3/31/2019	710	7	N/A	73	N/A
12/31/2018	668	72	N/A	77	N/A
9/30/2018	632	68	N/A	74	N/A
6/30/2018	488	35	N/A	78	N/A
3/31/2018	498	47	N/A	76	N/A
12/31/2017	510	-2	N/A	81	N/A
9/30/2017	527	11	N/A	96	N/A
6/30/2017	669	56	N/A	85	N/A
3/31/2017	634	47	N/A	82	N/A
12/31/2016	600	-51	N/A	71	N/A
9/30/2016	434	-85	N/A	40	N/A
6/30/2016	549	-73	N/A	38	N/A
3/31/2016	546	-74	N/A	39	N/A
12/31/2015	550	12	N/A	28	N/A
9/30/2015	553	14	N/A	44	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AZTA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.7%).

Beneficios vs. Mercado: Se prevé que AZTA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que AZTA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (4.2% al año) de AZTA crezcan más despacio que el mercado de US (13.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.2% al año) de AZTA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AZTA sea baja dentro de 3 años (0.6%).

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/10 16:15
Precio de las acciones al final del día	2026/09/10 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/09/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Azenta, Inc. está cubierta por 14 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Christopher Muse	Barclays
Brett Hodess	BofA Global Research
Paul Knight	Brean Capital Historical (Janney Montgomery)

Azenta Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 19% to US$31.20

Price target decreased by 8.4% to US$35.40

Azenta, Inc. Reiterates Earnings Guidance for Full Year Fiscal 2026

Price target increased by 13% to US$39.60

Price target increased by 8.2% to US$36.60

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2026

Recent updates

AZTA: Leadership Transition And Index Inclusion Will Shape A Measured Sentiment Recovery

Azenta Names Interim CEO After Marotta Resigns and Launches Search for Successor

Azenta, Inc. Announces CEO Changes, Effective August 22, 2026

AZTA: Higher Guidance And Buybacks Will Offset Future P/E Compression Risks

Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue

Azenta, Inc. Announces Appointment of Erik J. Bello as Chief Accounting Officer, Effective August 31, 2026

Azenta Lifts 2026 Guidance and Concludes $50 Million Buyback as Quarterly Profit Returns

Third quarter 2026 earnings: EPS and revenues exceed analyst expectations

Price target increased by 19% to US$31.20

AZTA: Index Additions And Refined Assumptions Will Support Gradual Sentiment Recovery

Azenta, Inc. to Report Q3, 2026 Results on Aug 04, 2026

AZTA: Portfolio Refocus And Index Additions Will Support Future Upside Potential

Azenta Finalizes B Medical Systems Sale to Refocus on Core Life Sciences

AZTA: Future P/E Compression And Impairment Charges Will Pressure Returns

AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery

Now 20% undervalued

AZTA: 2026 Execution Reset And Impairment Resolution Will Support Sentiment Recovery

Now 21% undervalued after recent price drop

Azenta Faces Revenue Challenges and Goodwill Impairment With Delayed Asset Sale and Leadership Changes

Independent Director recently bought US$164k worth of stock

AZTA: 2026 Guidance And Calibrated Expectations Will Support Sentiment Recovery

Azenta, Inc. Reports Impairment Charges for the Second Quarter Ended March 31, 2026

Now 60% undervalued after recent price drop

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta, Inc. to Report Q2, 2026 Results on May 06, 2026

Price target decreased by 8.4% to US$35.40

AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery

Azenta, Inc. Announces Executive Changes

AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery

High number of new directors

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

Azenta, Inc. Reiterates Earnings Guidance for Full Year Fiscal 2026

AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential

Azenta, Inc. Announces Resignation of Alan P. Malus from Board of Directors and Member of Human Resources and Compensation Committee, Effective January 29, 2026

Azenta, Inc. to Report Q1, 2026 Results on Feb 04, 2026

AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward

AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential

Azenta, Inc., Annual General Meeting, Jan 28, 2026

AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion

Azenta, Inc. (NasdaqGS:AZTA) announces an Equity Buyback for $250 million worth of its shares.

Azenta, Inc. announced delayed annual 10-K filing

AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Price target increased by 13% to US$39.60

Full year 2025 earnings: EPS misses analyst expectations

Price target increased by 8.2% to US$36.60

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2026

AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity

Azenta, Inc. to Report Q4, 2025 Results on Nov 21, 2025

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

Forecast breakeven date pushed back to 2027

Now 20% undervalued after recent price drop

Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Third quarter 2025 earnings released: EPS: US$0.015 (vs US$0.12 loss in 3Q 2024)

Azenta, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025

Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Azenta, Inc. to Report Q3, 2025 Results on Aug 05, 2025

Azenta, Inc Announces Resignation of Violetta Hughes as Chief Accounting Officer, Effective August 2025

Azenta, Inc.(NasdaqGS:AZTA) dropped from Russell 1000 Dynamic Index

Price target decreased by 21% to US$32.25

Now 20% undervalued after recent price drop

Pharma And Biotech Outsourcing Will Shape Future Market Dynamics

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind